The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents

  title={The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents},
  author={Heather B. Jaspan and Stephen D. Lawn and Jeffrey T. Safrit and Linda-Gail Bekker},
Inclusion of children and adolescents in clinical trial research and particularly HIV vaccine trials is difficult. Ethico-legal issues concerning age of informed consent protection of children and reporting of illegal sexual activity and sexually transmitted diseases confront researchers. Socio-behavioral issues include assessment of true understanding of the consent form and possible disinhibition of sexual behaviour whilst participating in trials. There is also a lack of experience in… 

Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.

Critical issues and special challenges in the development and implementation of HIV vaccine trials in adolescents must be addressed, including regulatory considerations, potential differentials in safety and immunogenicity, alternative trial design strategies, recruitment and retention challenges, community involvement models, and approaches to informed consent/assent are addressed.

Immunology of infants through adolescents: responses to emulate for HIV vaccines

Differential immune maturity in these age groups may significantly impact vaccine efficacy, and should be taken into account when developing vaccines, with an emphasis on the immune response to vaccines for HIV and other pathogens.

Protecting South Africa's children from HIV; giving them our best shot

There is a moral imperative to resolve ethical and legal complexities in a broader debate so that develop and test vaccines in a way that both protects and promotes the health of young people.

Meeting the goal of concurrent adolescent and adult licensure of HIV prevention and treatment strategies

The ability of adolescents to access safe and effective new products for HIV prevention and treatment is optimised by adolescent licensure at the same time these products are approved and marketed

Vaccination Age Changing from Infancy and Childhood to Adolescence andAdulthood: An In-Dispensable Approach in Immunization Programs

The revision of vaccination age changing in order to maintain newborns/children's health and to prevent the return of infectious diseases is required.

Potential Behavioural and Psychological Contributions to Ethical HIV Vaccine Trials in South Africa

The development of an HIV vaccine is one of the best hopes for the future of the HIV pandemic. HIV vaccine trials involve multiple disciplines and professions, including psychologists and other

The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants

The data support the inclusion of younger participants who are at risk for HIV in future HIV vaccine efficacy trials and Motivations for trial enrolment, social harms, adverse events and loss to follow-up were compared.

Broadening inclusion of vulnerable populations in HIV vaccine trials

An integrated strategy to HIV vaccine development should include infants of HIV-infected women, adolescents and injection drug users, to ensure vaccine licensure for use in a broad range of at-risk populations from the outset.

Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials.

  • H. JaspanJ. Berwick L. Bekker
  • Medicine
    The Journal of adolescent health : official publication of the Society for Adolescent Medicine
  • 2006



Challenges to Conducting HIV Preventative Vaccine Trials With Adolescents

The issues surrounding HIV vaccine trials with adolescents are identified, plans and implications for the implementation of these trials are addressed, and what progress has been made are discussed.

Preventing neonatal HIV: a review.

This data indicates that where safe and compliant formula feeding is difficult, avoidance of mixed feeding may improve infant outcomes, however, post-natal transmission via breast milk remains a major challenge.

HIV vaccines in infants and children: past trials, present plans and future perspectives.

  • J. Safrit
  • Medicine
    Current molecular medicine
  • 2003
This review will address the recent history in HIV vaccine trials in the pediatric population while giving due respect to the pediatric vaccine successes achieved over the past decades. Success and

Lessons from failure--preparing for future HIV-1 vaccine efficacy trials.

The vaccine did not prevent HIV-1 acquisition and there was no overall protective effect, and exploratory subgroup analyses showed nonsignificant trends toward efficacy in preventing infection in the highest risk and nonwhite volunteers.

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design

The focus of this article is to review the importance of antibodies and the strategies that are currently being used for inducing such antibodies, and to recommend strategies that may facilitate the clearance of virally infected cells.

Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum.

The SPf66 synthetic vaccine is safe and partly efficacious against Plasmodium falciparum malaria among children 1-5 years old and may require trials to evaluate safety, immunogenicity, and efficacy when administered in the first year of life.

Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone.

Mucosal immunity of the adolescent female genital tract.